iRhythm Technologies, Inc. (IRTC) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
iRhythm Technologies, Inc.
Address
699 8th Street
San Francisco, CA 94103
United States of America (the)
Phone
415 632 5700
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
2400
First IPO Date
October 20, 2016
Key Executives
| Name | Title | Pay | Year Born |
| Quentin S. Blackford | President, Chief Executive Officer & Director | 2.08M | 1979 |
| Daniel G. Wilson | Chief Financial Officer & Principal Financial Officer | 970,199 | 1982 |
| Patrick Michael Murphy | Chief Business & Legal Officer | 987,343 | 1979 |
| Minang Turakhia | Chief Medical & Scientific Officer and Executive Vice President of Advanced Technologies | 1.03M | 1974 |
| Chad Patterson | Chief Commercial and Product Officer | 1.28M | 1982 |
| Brian Lawrence | Executive Vice President & Chief Technology Officer | 0 | 1970 |
| Lisa Pecora | Senior Vice President of Finance & Investor Relations | 0 | N/A |
| Marc Rosenbaum | Senior Vice President of Finance & Chief Accounting Officer | 0 | 1973 |
| Sean Clinton Freeman | Executive Vice President of Strategy & Corporate Development | 0 | 1976 |
| Mervin Smith | Executive Vice President of Business Operations | 0 | 1975 |
Description
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
